Episodi
-
In this episode of the Oncology Brothers podcast, hosts Drs. Rahul and Rohit Gosain are joined by esteemed palliative care experts Dr. Janet Abrahm from Dana-Farber Cancer Institute and Dr. Ishwaria Subbiah from Sarah Cannon Research Institute. Together, they delve into the critical topic of palliative care, exploring its evolution from a focus on end-of-life care to an integral part of cancer treatment that enhances both longevity and quality of life.
Key discussion points include:â˘â â The definition and importance of palliative care as an "extra layer of support" for patients, families, and oncologists.â˘â â The stigma surrounding palliative care and the potential benefits of rebranding it as supportive care.â˘â â The significant impact of palliative care on symptom management and overall patient outcomes.â˘â â Innovative approaches to integrating palliative care into oncology practices, including the use of technology and multidisciplinary teams.â˘â â Effective communication strategies for discussing palliative care and advanced care planning with patients and their families.
Join us for this enlightening conversation that aims to demystify palliative care and highlight its essential role in cancer care. Don't forget to like, subscribe, and share your thoughts in the comments!#OncologyBrothers #PalliativeCare #CancerCare #SupportiveCare #QualityOfLife #SymptomManagement #AdvancedCarePlanning
Website: http://www.oncbrothers.com/
X/Twitter: https://twitter.com/oncbrothers
Contact us at [email protected]
-
In this episode of the Oncology Brothers podcast, hosts Drs. Rahul and Rohit Gosain welcome Dr. Martina Murphy, an Associate Professor of Medicine and Senior Associate Dean of Graduate Medical Education at the University of Florida, to discuss the current landscape of ovarian cancer.
Join us as we dive into the critical aspects of diagnosing and managing ovarian cancer, including:â˘â â The importance of surgical staging and primary debulking surgeryâ˘â â The role of genetic testing, including BRCA and NGS, in treatment planningâ˘â â Adjuvant therapy options, focusing on platinum-based chemotherapy and the use of Bevacizumabâ˘â â Insights into PARP inhibitors and their application in BRCA-positive and wild-type patientsâ˘â â Navigating treatment options for relapsed and refractory ovarian cancer, including the use of antibody-drug conjugates like Mirvetuximab and Trastuzumab Deruxtecan (TDXd).
Dr. Murphy shares her expertise on the latest advancements in ovarian cancer treatment, the significance of genetic testing, and the management of side effects associated with various therapies.
Tune in for a comprehensive overview of the standard of care for ovarian cancer and the evolving treatment landscape. Don't forget to check out our other episodes for more discussions on practice-changing data and current treatment options in oncology!
Subscribe to the Oncology Brothers podcast for more insights and updates in the field of oncology!
Website: http://www.oncbrothers.com/
X/Twitter: https://twitter.com/oncbrothers
Contact us at [email protected]
-
Episodi mancanti?
-
Join us for an insightful episode of the Oncology Brothers podcast as we dive deep into the world of gynecologic oncology, focusing specifically on endometrial cancer. Hosted by Drs. Rohit and Rahul Gosain, this episode features Dr. Shannon Westin, a Professor of Gynecology, Oncology, and Reproductive Medicine at the MD Anderson Cancer Center.
In this episode, we explored:â˘â â The different histologies of endometrial cancer, including endometrioid, serous, clear cell, and undifferentiated types.â˘â â The evolving landscape of molecular classification and its impact on treatment decisions.â˘â â The current treatment paradigms for early-stage and advanced endometrial cancer, including the role of surgery, chemotherapy, and immunotherapy.â˘â â The significance of NGS (Next-Generation Sequencing) testing in identifying actionable mutations, such as MSI-high tumors and HER2-positive cancers.â˘â â The latest advancements in adjuvant therapies and the potential of combining chemotherapy with immunotherapy.
Whether you're a healthcare professional or simply interested in the latest developments in cancer treatment, this episode is packed with valuable insights and expert opinions. Don't forget to like, subscribe, and check out our other discussions focusing on ovarian cancer and more!
Website: http://www.oncbrothers.com/
X/Twitter: https://twitter.com/oncbrothers
Contact us at [email protected]
-
In this episode of the Oncology Brothers podcast, hosts Drs. Rahul and Rohit Gosain dive into the recent FDA approval of tarlatamab, a groundbreaking bispecific antibody for patients with extensive stage small cell lung cancer. Joined by Dr. Misty Shields from Indiana University, they explore the DeLLphi-301 study design, the efficacy of tarlatamab, and the operational challenges associated with its use.
Key topics discussed include:â˘â â The study's primary endpoint of objective response rate and its implications for patient care.â˘â â The unique mechanism of action of tarlatamab targeting DLL3 and CD3 T cells.â˘â â The importance of monitoring for side effects such as cytokine release syndrome (CRS) and immune cell-associated neurotoxicity syndrome (ICANS).â˘â â Strategies for community oncologists to effectively manage patients receiving this new treatment.
Dr. Shields also highlights the significance of patient advocacy and the role of organizations like Longevity Small Cell Smashers in supporting those affected by small cell lung cancer.
Tune in for an insightful discussion that sheds light on the future of treatment options for small cell lung cancer and the collaborative efforts needed to ensure patient safety and care.
Don't forget to like, subscribe, and hit the notification bell for more updates on the latest in oncology!
Website: http://www.oncbrothers.com/
X/Twitter: https://twitter.com/oncbrothers
Contact us at [email protected]
-
Welcome to another episode of the Oncology Brothers podcast! In this episode, hosts Drs. Rahul and Rohit Gosain dive into the recent approval of Durvalumab in the perioperative settings for non-small cell lung cancer, based on the AEGEAN trial.
Join us as we welcome Dr. Sandip Patel, a medical oncologist from UCSD, and Dr. Mara Antonoff, a thoracic surgeon from MD Anderson, to discuss the implications of this new treatment option. We explore the study design of the AEGEAN trial, its differences from other trials like Keynote 671, and the importance of a multidisciplinary approach in managing lung cancer patients.
Key topics include: â˘â â Overview of the AGEAN trial and its findings â˘â â The significance of neoadjuvant and adjuvant therapies â˘â â The role of surgical evaluation and molecular profiling â˘â â Insights on patient selection and treatment strategies
As we shift towards more perioperative and postoperative treatments, understanding the nuances of these approaches is crucial for optimizing patient outcomes. Tune in for valuable insights and discussions that can help shape your practice!
Don't forget to like, subscribe, and hit the notification bell for more episodes on recent approvals and practice-changing data in oncology! #OncologyBrothers #LungCancer #Dervalumab #AEGEANTrial #MultidisciplinaryCare #MedicalOncology #ThoracicSurgery
Website: â http://www.oncbrothers.com/ â
X/Twitter: â https://twitter.com/oncbrothers â
Contact us at [email protected]
-
Welcome to the Oncology Brothers podcast! In this episode, hosts Drs. Rahul and Rohit Gosain are joined by Dr. Stephen Liu, Associate Professor and Director of Thoracic Oncology at the Georgetown Lombardi Comprehensive Cancer Center. Together, they dive into the latest findings from ESMO 2024, focusing on key studies in lung cancer that every community oncologist should be aware of.
Episode Highlights:â˘â â LAURA Trial: Discussing the role of osimertinib in locally advanced unresectable EGFR-mutant lung cancer post-chemoradiation and its impact on CNS progression-free survival.â˘â â MARIPOSA and MARIPOSA-2 Studies: Exploring the importance of amivantamab in metastatic non-small cell lung cancer, including insights on resistance patterns and treatment sequencing.â˘â â ADRIATIC Study: Analyzing the use of durvalumab as consolidation therapy in limited-stage small cell lung cancer and its implications for practice, including updates on prophylactic cranial irradiation (PCI).
Join us as we unpack these pivotal studies that are shaping the future of lung cancer treatment. Don't forget to check out our highlights on GI, GU, and breast cancer from ESMO 2024!
Subscribe for more insights and updates in oncology!
Website: http://www.oncbrothers.com/
X/Twitter: https://twitter.com/oncbrothers
Contact us at [email protected]
-
In this episode of the Oncology Brothers Podcast, hosts Drs. Rohit and Rahul Gosain welcome Dr. Shernan Holtan from Roswell Park Comprehensive Cancer Center to discuss the recent approval of Axatilimab, a novel monoclonal antibody for the treatment of chronic graft-versus-host disease (GVHD).
Join us as we explore the differences between acute and chronic GVHD, the challenges faced by community oncologists in managing this condition, and the exciting results from the AGAVE-201 study that led to Axatilimab's FDA approval. Dr. Holtan shares insights on the drug's mechanism of action, its dosing regimen, and the importance of patient-reported outcomes in assessing treatment efficacy.
We also delve into the safety profile of Axatilimab, discussing potential side effects, infusion reactions, and the significance of partnering with tertiary care centers for optimal patient management.
Whether you're a healthcare professional or simply interested in the latest advancements in oncology, this episode provides valuable information on managing chronic GVHD and improving patient quality of life.
Don't forget to like, subscribe, and check out our other episodes for more discussions on recent approvals and the current standard of care for various malignancies!#OncologyBrothers #GVHD #Axatilimab #ChronicGVHD #CancerCare #Podcast
Website: http://www.oncbrothers.com/
X/Twitter: https://twitter.com/oncbrothers
Contact us at [email protected]
-
In this episode of the Oncology Brothers podcast, hosts Drs. Rahul and Rohit Gosain are joined by Dr. Mikkael Sekeres, Professor of Medicine and Chief of the Division of Hematology at the University of Miami. Together, they explore the complex landscape of acute myeloid leukemia (AML), discussing the latest advancements in diagnosis, treatment options, and risk stratification.
Key topics included:
â˘â â The importance of molecular testing in AML diagnosis and treatment planning
â˘â â The role of intensive induction chemotherapy and the classic 7+3 regimen
â˘â â New oral therapies, including FLT3 inhibitors and hypomethylating agents combined with venetoclax
â˘â â Strategies for managing elderly or frail patients who are ineligible for intensive chemotherapy
â˘â â The significance of measurable residual disease (MRD) in treatment decisions and transplant eligibility
â˘â â Insights into managing side effects and complications associated with AML treatments
Join us for an informative discussion that sheds light on the evolving treatment landscape of AML and the importance of personalized care in oncology. Don't forget to check out our other episodes on hematological malignancies, and we look forward to seeing you at ASH 2024!
Subscribe to our channel for more insights and updates in the world of oncology!
Website: http://www.oncbrothers.com/
X/Twitter: https://twitter.com/oncbrothers
Contact us at [email protected]
-
Join us in this exciting episode of the Oncology Brothers podcast as we dive into the highlights from ESMO 2024, focusing on gastrointestinal malignancies. Hosts Drs. Rohit and Rahul Gosain are joined by Dr. Kristen Ciombor, a GI medical oncologist from Vanderbilt University, to discuss four key studies that have significant implications for clinical practice.
In this episode, we covered:â˘â â LEAP-012 Study: An update on HCC treatment with Lenvatinib and Pembrolizumab combined with TACE, exploring the promising progression-free survival (PFS) data and the need for mature overall survival (OS) results.â˘â â Keynote-811: The current standard of care for HER2-positive gastroesophageal junction and gastric adenocarcinoma, highlighting improved OS with Pembrolizumab, chemotherapy, and Trastuzumab.â˘â â POD1UM-303 Trial: A groundbreaking study in metastatic anal cancer that shows significant OS improvement with the addition of the PD-1 inhibitor Retifanlimab to chemotherapy.â˘â â NICHE-2 Study: A remarkable update on MSI-high patients, showcasing a 100% three-year disease-free survival rate with neoadjuvant immunotherapy.
Tune in for an insightful discussion that will keep you updated on the latest advancements in GI oncology! Don't forget to like, subscribe, and hit the notification bell for more conference highlights and oncology discussions.#OncologyBrothers #ESMO24 #GIMalignancies #CancerResearch #Podcast
Subscribe for more updates and insights from the Oncology Brothers!
Website: http://www.oncbrothers.com/
Twitter: https://twitter.com/oncbrothers
Contact us at [email protected]
-
Join us as we dive into four pivotal studies:
1.â â NIAGARA Trial: Explore the groundbreaking findings on the combination of chemotherapy and immunotherapy in the perioperative setting for patients with resectable muscle-invasive bladder cancer, which may now set a new standard of care.
2.â â TiNiVO-2 Study: Learn why re-challenging patients with immunotherapy after progression on prior immunotherapy is not recommended, and what alternative treatments may be more effective.
3.â â PEACE-3 Study: Discover the implications of combining enzalutamide with radium-223 in metastatic castration-resistant prostate cancer and its impact on progression-free survival.
4.â â CONTACT-02 Study: Understand the results comparing cabozantinib with atezolizumab against a second novel hormonal therapy, and what this means for overall survival in specific patient populations.
Tune in for an insightful discussion that highlights the latest advancements in GU cancer treatment and their potential impact on clinical practice. Don't forget to check out our other episodes covering breast cancer, lung cancer, and GI malignancies from ESMO 2024!
Subscribe for more updates and insights from the Oncology Brothers!
Website: http://www.oncbrothers.com/
Twitter: https://twitter.com/oncbrothers
Contact us at [email protected]
-
Welcome to the Oncology Brothers podcast! In this episode, hosts Drs. Rahul and Rohit Gosain are joined by Dr. Paolo Tarantino from the Dana-Farber Cancer Institute to discuss the latest highlights from ESMO 2024, focusing on groundbreaking studies in breast cancer.
Join us as we dive into three key abstracts that have the potential to impact current clinical practice:
1.â NATALEE Trial: Discover how the addition of ribociclib to endocrine therapy has shown improved invasive disease-free survival in early-stage breast cancer, including node-negative patients. Ribociclib was recently approved for this indication, and we discuss its implications for patient care.
2.â â Keynote 522 Update: We explore the updated results demonstrating an overall survival benefit with the perioperative use of pembrolizumab in combination with neoadjuvant chemotherapy for early-stage triple-negative breast cancer. This regimen continues to be a standard of care.
3.â â DESTINY Breast-12: Learn about the promising intracranial activity of trastuzumab durextecan in HER2-positive breast cancer patients with brain metastases, showcasing its potential to change treatment trajectories.
Tune in for an insightful discussion that highlights the evolving landscape of breast cancer treatment and offers hope for patients. Don't forget to check out our other episodes covering GI, lung, and GU cancer conference highlights!
Subscribe for more updates and insights from the Oncology Brothers!
Website: http://www.oncbrothers.com/
Twitter: https://twitter.com/oncbrothers
Contact us at [email protected]
-
Welcome to the Oncology Brothers podcast! In this episode, hosts Drs. Rahul and Rohit Gosain are joined by Dr. Gilberto Lopes, Chief of Medical Oncology at the Sylvester Comprehensive Cancer Center, to discuss the highlights from the World Conference on Lung Cancer 2024.
Join us as we dive into four key studies that could reshape our understanding and approach to lung cancer treatment:
1. Checkmate 816 vs. Checkmate 77T: An exploratory analysis of neoadjuvant chemoimmunotherapy and the ongoing debate about the benefits of post-operative immunotherapy.
2. SKIPPirr Study: Discover how prophylactic strategies can reduce infusion-related reactions with amivantamab.
3. HARMONi-2: A look at a novel PD-1 and VEGF inhibitor compared to Pembrolizumab in metastatic non-small cell lung cancer.
4. TROPION-Lung01: Insights into the performance of the antibody-drug conjugate Dato-DXd against docetaxel, particularly in non-squamous histology.
Tune in for an informative discussion that highlights the latest advancements in lung cancer research and treatment strategies.
Don't forget to like, subscribe, and check out our other episodes for more insights into the current standard of care in oncology!
#OncologyBrothers #LungCancer #WCLC2024 #CancerResearch #MedicalOncology
Website: http://www.oncbrothers.com/
Twitter: https://twitter.com/oncbrothers
Contact us at [email protected]
-
Join the Oncology Brothers, Drs. Rahul and Rohit Gosain, as they dive into the world of Chronic Myeloid Leukemia (CML) with world-renowned hematologist Dr. Jorge Cortes from the Georgia Cancer Center. In this episode, they discuss the current standard of care treatment options for CML, including risk stratification, monitoring, treatment algorithms, and side effects of first, second, and third-generation TKIs.
Dr. Cortes provides valuable insights on when to consider treatment holidays, switching therapies, and the potential benefits of upcoming treatments like asciminib. The discussion also covers the importance of deep molecular responses, the role of bone marrow biopsies, and the decision-making process for patients in accelerated phase CML.
Tune in to gain a comprehensive understanding of managing CML patients in the community setting and stay updated on the latest advancements in hematology and oncology. Don't miss out on this informative episode with the Oncology Brothers podcast!
Website: http://www.oncbrothers.com/
Twitter: https://twitter.com/oncbrothers
Contact us at [email protected]
-
In this episode of the Oncology Brothers podcast, Drs. Rahul & Rohit Gosain are joined by Dr. Pallawi Torka from Memorial Sloan Kettering Cancer Center to discuss the current treatment landscape for low-grade lymphomas, specifically follicular and mantle cell lymphoma.
Key Points Covered:â˘â â Follicular Lymphoma: The discussion includes the minimum workup required for treatment planning, frontline treatment options, nuances of PFS with different anti-CD20 agents, and considerations for relapse or refractory cases.â˘â â Mantle Cell Lymphoma: The conversation delves into initial treatment paradigms, the role of BTK inhibitors, considerations for TP53 mutations, and options for relapsed or refractory cases, including the growing importance of CAR T cell therapy.
Highlights:â˘â â Treatment Options: From chemoimmunotherapy to novel agents like BTK inhibitors and CAR-T cell therapy, the podcast explores the evolving landscape of treatment options for these low-grade lymphomas.â˘â â TP53 Mutations: The discussion sheds light on how treatment decisions are influenced by the presence of TP53 mutations, with a focus on recent studies and promising combinations.â˘â â Relapse Management: Insights are shared on managing relapsed or refractory cases, including the role of BTK inhibitors, CAR-T cell therapy, and other emerging options.
Join the Oncology Brothers as they navigate through the complexities of treating low-grade lymphomas with expert insights from Dr. Torka. Stay informed about the latest advancements in oncology and the changing standards of care for these challenging diseases.
Website: http://www.oncbrothers.com/
Twitter: https://twitter.com/oncbrothers
Contact us at [email protected]
-
Welcome back to the Oncology Brothers podcast! In this episode, hosts Drs. Rahul and Rohit Gosain dive into the world of diffused large B-cell lymphoma with special guest Dr. Carla Casulo from the Wilmot Cancer Institute in Rochester, New York.
Key Points Covered:â˘â â Understanding the importance of accurate diagnosis through excisional biopsy in diffused large B-cell lymphoma.â˘â â Exploring the significance of cell of origin in guiding treatment decisions.â˘â â Initial treatment approaches for stage 1 and 2 disease, including the use of Polatuzumab based on the POLARIX trial.â˘â â Treatment options for relapsed or refractory disease, including CAR-T therapy, BiTE therapy, and anti-CD19 antibody agents.â˘â â Managing toxicities associated with different treatment regimens, such as cytopenias, infections, and neurotoxicity.
Join us as we unravel the complexities of diffused large B-cell lymphoma and discuss the latest advancements in treatment options with Dr. Carla Casulo. Stay informed and up to date with the Oncology Brothers podcast!
Don't forget to like, share, and subscribe for more insightful discussions on oncology topics. Thank you for tuning in to the Oncology Brothers podcast.
Website: http://www.oncbrothers.com/
Twitter: https://twitter.com/oncbrothers
Contact us at [email protected]
-
In this episode of the Oncology Brothers podcast, Dr. Allison Betof Warner from Stanford University joins hosts Drs. Rahul and Rohit Gosain discuss the current standard of care and recent advances in cutaneous melanoma treatment.
Key Points Covered:â˘â â Early Stage Melanoma: Discussion on the standard of care for different stages, including the role of neoadjuvant immunotherapy.â˘â â Adjuvant Therapy: Controversies and considerations for stage 2 and beyond, including the use of ctDNA as a predictive tool.â˘â â Neoadjuvant Therapy: Insights into recent trials and the evolving landscape of neoadjuvant treatment for melanoma.â˘â â Metastatic Stage: Exploration of treatment options, including immunotherapy combinations and BRAF MEK inhibitors.â˘â â TILS Therapy: Overview of the recent approval of Tumor Infiltrating Lymphocytes (TILS) therapy for melanoma patients.
Stay informed on the latest in melanoma treatment by listening to this insightful discussion with Dr. Warner. Don't miss out on valuable insights that can impact patient care and treatment decisions. Subscribe now to the Oncology Brothers podcast for more updates on oncology practices and advancements.
Website: http://www.oncbrothers.com/
Twitter: https://twitter.com/oncbrothers
Contact us at [email protected]
-
Welcome to another episode of the Oncology Brothers podcast! In this enlightening discussion, Rohit and Rahul Gosain delve into the crucial topic of cardio-oncology with special guest Dr. Susan Dent, President of the International Cardio-Oncology Society.
Discover the intersection between cardiology and oncology, exploring the importance of treating the whole patient, not just the cancer. Dr. Dent sheds light on key cardiovascular risks and toxicities associated with various cancer treatments, from anthracyclines to immune checkpoint inhibitors.
Learn about the necessity of collaboration between oncologists and cardiologists, especially in assessing cardiovascular risk factors and monitoring patients throughout their cancer therapy. Dr. Dent also touches on the significance of early intervention and prevention strategies to safeguard patients' cardiovascular health.
Join the Oncology Brothers as they emphasize the proactive approach to cardio-oncology, aiming to not only cure cancer but also save hearts. Stay informed, stay proactive, and tune in for more insightful discussions on cancer care. Don't miss out on this informative episode!
Website: http://www.oncbrothers.com/
Twitter: https://twitter.com/oncbrothers
Contact us at [email protected]
-
In this episode of the Oncology Brothers podcast, hosts Rahul and Rohit Gosain are joined by Dr. Patrick Forde from the Johns Hopkins University to discuss the latest advancements in early stage non-small cell lung cancer. The conversation delves into treatment options for resectable and unresectable disease, including the use of neoadjuvant and perioperative therapies, as well as the role of immunotherapy in different scenarios. Dr. Forde provides insights on actionable mutations, adjuvant treatments, and the impact of targeted therapies like osimertinib and alectinib have.
Tune in to learn about the current standard of care for early stage non-small cell lung cancer and gain valuable clinical pearls from this informative discussion.
Don't miss out on this insightful episode of the Oncology Brothers podcast!
Website: http://www.oncbrothers.com/
Twitter: https://twitter.com/oncbrothers
Contact us at [email protected]
-
Welcome back to the Oncology Brothers podcast! In this episode, hosts Drs. Rahul and Rohit Gosain are joined by Dr. Isabel Preeshagul from Memorial Sloan Kettering Cancer Center to discuss metastatic non-small cell lung cancer treatment without actionable mutations in first-line settings.
They dive into the importance of comprehensive testing, strategies for using immunotherapy and chemotherapy combinations, and emerging second-line treatment options. Dr. Preeshagul shares insights on targeting KRAS G12C, HER2 mutation with TDXD, and the potential combination of ramucirumab with pembrolizumab.
Tune in for a detailed discussion on the latest advancements in non-small cell lung cancer treatment. Don't miss out on valuable insights from this informative episode of the Oncology Brothers podcast!
-
Welcome to the Oncology Brothers Podcast! Join Drs. Rahul & Rohit Gosain in this episode as they welcome Dr. Balazs Halmos, a thoracic medical oncologist from Montefiore-Einstein Comprehensive Cancer Center, to discuss the current landscape of metastatic non-small cell lung cancer with actionable mutations in first-line settings.
In this informative episode, they cover a wide range of topics including the importance of NGS testing, treatment options for various actionable mutations such as EGFR, ALK, ROS1, RET rearrangements, and more. Dr. Halmos provides valuable insights into decision-making processes, sequencing treatments, and managing toxicities associated with targeted therapies.
Don't miss out on this insightful discussion that sheds light on the rapidly evolving space of precision medicine in lung cancer treatment. Stay informed and learn how identifying and targeting specific mutations can optimize treatment outcomes and improve patient quality of life.Tune in to the Oncology Brothers Podcast for expert insights and discussions on the latest developments in oncology.
Subscribe now to stay updated on their informative episodes!
- Mostra di più
